ilixadencel
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02432846)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- intuvax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03735290 | Phase 1/Phase 2 (Phase 2) | Jan 14, 2019 | Immunicum AB, PPD |
| NCT02686944 | Phase 1 | Jun 1, 2016 | Immunicum AB |
| NCT02432846 | Phase 2 | Apr 1, 2015 | Accelovance, Immunicum AB, TFS Trial Form Support |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunicum AB | For profit | 3 | 3 | 2 | 2015 |
| Accelovance | For profit | 1 | 0 | 1 | 2015 |
| PPD | For profit | 1 | 0 | 1 | 2019 |
| TFS Trial Form Support | For profit | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1